Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02343679
Title Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Anne Beaven, MD
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Duke University Medical Center Durham North Carolina 27710 United States Details
*Shaded cells indicate that there was no data available from for the field